The innovators working to make in vivo cell therapy a reality
This image was generated by AI and may not depict real events.
Investors are showing interest in in vivo cell therapies, driving innovation among suppliers to overcome technical challenges. Recent acquisitions and emerging clinical data indicate the modality's potential for commercial success.
In vivo cell therapies involve delivering genes directly to patients through vectors like modified viruses or lipid nanoparticles. Unlike existing ex vivo treatments, this approach alters cell function in the body. Recent high-profile acquisitions, including AstraZeneca's $1bn purchase of EsoBiotec and Eli Lilly's $2.4bn acquisition of Orna Therapeutics, highlight growing interest. Clinical trials are underway, with promising interim results reported for in vivo CAR-T therapies. The next 12 months will be crucial as more comprehensive data emerges, and investors remain eager to understand the technology's risks and potential.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.